Overview

Evaluation of Efficacy and Safety of Rituximab in Patients With Progressive Interstitial Lung Disease (ILD) With Inflammatory Component: a Multicentre Double-blind Placebo-controlled Randomized Trial

Status:
Not yet recruiting

Trial end date:
2026-06-15

Target enrollment:

Participant gender:

Summary

The main objective of the EvER-ILD2 study is to evaluate the efficacy on lung function at 6 months of one course rituximab (2 infusions) comparatively to one course of placebo (2 infusions) in a broad range of progressive ILD patients with inflammatory component.

Phase:

Phase 3

Details

Lead Sponsor:

University Hospital, Tours

Treatments:

Rituximab